<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131127">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01917877</url>
  </required_header>
  <id_info>
    <org_study_id>QCH-20030801</org_study_id>
    <nct_id>NCT01917877</nct_id>
  </id_info>
  <brief_title>Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab</brief_title>
  <official_title>Phase II Study of Bevasizumab in the Management of Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao Central Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the radiosensitivity of the lung, radiation-induced and chemotherapy-induced
      pneumonitis and pulmonary fibrosis are frequent happened following cancer therapy. It not
      only compromise cancer treatment, but also influence patient's life qualities and even
      death. there are no specific treatment modalities for this treatment-induced complication.
      Bevasizumab (Avastin), a VEGF inhibitor, can attenuate serum high expression VEGF and
      pulmonary permeability, maybe effective in the control acute pulmonary fibrosis. Patients
      will be randomized to receive Bevasizumab (7mg/kg iv) on day one and 21, followed by
      Dexamethasone ï¼ˆ10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20) or Dexamethasone alone.
      The thoracic CT, plasma TNF-a, IL-6, VEGF and C-reactive protein are accessed on before
      treatment, 24 hours after Bevasizumab, 7 days, 4 and 8 weeks. the target sample size is 30
      cases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>pulmonary function</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>thoracic CT scan</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>Avastin (Genentech/Roche)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosed cancer treatment-induced acute pulmonary fibrosis

        Exclusion Criteria:

          -  chronic pulmonary fibrosis and infection-induced pulmonary fibrosis

          -  active bleeding

          -  uncontrolled high blood pressure

          -  unstable systemic disease

          -  prior exposure to VEGF inhibitor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>youxin ji, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qingdao Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>youxin ji, md</last_name>
    <phone>86532-68665078</phone>
    <email>ji6677@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qingdao Central Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>youxin ji, md</last_name>
      <phone>86-532-68665078</phone>
    </contact>
    <investigator>
      <last_name>youxin ji, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>August 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Becacizumab</keyword>
  <keyword>pulmonary fibrosis</keyword>
  <keyword>irradiation</keyword>
  <keyword>chemotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
